CancerDrs

Lung Cancer clinical trials in Minnesota

39 actively recruiting lung cancer trials at 45 sites across Minnesota.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Minnesota:
  • Riverwood Healthcare Center — Aitkin, Minnesota
  • Essentia Health - Baxter Clinic — Baxter, Minnesota
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Fairview Ridges Hospital — Burnsville, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Minnesota:
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Mercy Hospital — Coon Rapids, Minnesota
  • Essentia Health - Deer River Clinic — Deer River, Minnesota
  • Essentia Health Cancer Center — Duluth, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Minnesota:
  • Minnesota Oncology Hematology, P.A. — Burnsville, Minnesota
  • Minnesota Oncology Hematology, P.A. — Chaska, Minnesota
  • Allina Health Cancer Institute - Mercy Hospital — Coon Rapids, Minnesota
  • Minnesota Oncology Hematology, P.A. — Coon Rapids, Minnesota
  • Minnesota Oncology Hematology, P.A. — Edina, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Minnesota:
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Essentia Health - Deer River Clinic — Deer River, Minnesota
  • Essentia Health Saint Mary's - Detroit Lakes Clinic — Detroit Lakes, Minnesota
  • Essentia Health Cancer Center — Duluth, Minnesota
  • Essentia Health Hibbing Clinic — Hibbing, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Minnesota:
  • Allina Health Cancer Institute - Abbott Northwestern Hospital — Minneapolis, Minnesota
  • HealthPartners Cancer Research Center — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Minnesota:
  • Research Site — Duluth, Minnesota
  • Research Site — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Minnesota:
  • Miller-Dwan Hospital — Duluth, Minnesota
  • Mayo Clinic in Rochester — Rochester, Minnesota
  • Coborn Cancer Center at Saint Cloud Hospital — Saint Cloud, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Minnesota:
  • Mayo Clinic - Rochester /ID# 252052 — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as Fir…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06646276
Sites in Minnesota:
  • Local Institution - 0037 — Minneapolis, Minnesota
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a…

Sponsor: AbbVie
NCT ID: NCT07155187
Sites in Minnesota:
  • HealthPartners Cancer Research Center /ID# 277339 — Saint Louis Park, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Minnesota:
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Mercy Hospital — Coon Rapids, Minnesota
  • Essentia Health - Deer River Clinic — Deer River, Minnesota
  • Essentia Health Cancer Center — Duluth, Minnesota
  • Fairview Southdale Hospital — Edina, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in Minnesota:
  • Fairview Ridges Hospital — Burnsville, Minnesota
  • Minnesota Oncology - Burnsville — Burnsville, Minnesota
  • Cambridge Medical Center — Cambridge, Minnesota
  • Minnesota Oncology Hematology PA-Chaska — Chaska, Minnesota
  • Mercy Hospital — Coon Rapids, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Minnesota:
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Essentia Health - Deer River Clinic — Deer River, Minnesota
  • Essentia Health Cancer Center — Duluth, Minnesota
  • Essentia Health Saint Mary's Medical Center — Duluth, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Minnesota:
  • USOR Minnesota Oncology Hematology — Maplewood, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…

Sponsor: Synthekine
NCT ID: NCT05098132
Sites in Minnesota:
  • HealthPartners Cancer Center at Regions Hospital — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in th…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04665739
Sites in Minnesota:
  • Mayo Clinic in Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung…

Sponsor: Daiichi Sankyo
NCT ID: NCT06362252
Sites in Minnesota:
  • Regents of the University of Minnesota — Minneapolis, Minnesota
  • Mayo Clinic — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 wi…

Sponsor: BlossomHill Therapeutics
NCT ID: NCT06706076
Sites in Minnesota:
  • Mayo Clinic Hospital - Rochester, MN — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Minnesota:
  • Mayo Clinic Cancer Center — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…

Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Minnesota:
  • Health Partners Frauenshuh Cancer Center — Saint Louis Park, Minnesota
  • Health Partners Cancer Center at Regions Hospital — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment…

Sponsor: Masonic Cancer Center, University of Minnesota
NCT ID: NCT04105270
Sites in Minnesota:
  • MNCCTN Essentia Health St. Joseph's Brainerd Medical Center — Brainerd, Minnesota
  • MNCCTN Essentia Health Deer River — Deer River, Minnesota
  • MNCCTN Essentia Health St. Mary's Detroit Lakes Clinic — Detroit Lakes, Minnesota
  • MNCCTN Essentia Health Duluth — Duluth, Minnesota
  • MNCCTN Essentia Health Fosston — Fosston, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Sponsor: AstraZeneca
NCT ID: NCT06996782
Sites in Minnesota:
  • Research Site — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to rem…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07428044
Sites in Minnesota:
  • Mayo Clinic (Data Collection Only) — Rochester, Minnesota
View on ClinicalTrials.gov →

Showing 25 of 39 trials with sites in Minnesota. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19